Pexelizumab anti-C5补充抗体,作为辅助疗法的主要经皮冠状动脉介入急性心肌梗死:心肌梗死血管成形术治疗的补充抑制(逗号)试验。
文章的细节
-
引用
复制到剪贴板 -
格兰杰CB Mahaffey千瓦,韦弗WD,泰鲁P,招聘JS, Filloon TG,罗林斯,Todaro TG,尼克洛JC, Ruzyllo W,阿姆斯特朗PW
Pexelizumab anti-C5补充抗体,作为辅助疗法的主要经皮冠状动脉介入急性心肌梗死:心肌梗死血管成形术治疗的补充抑制(逗号)试验。
循环。2003年9月9日,108 (10):1184 - 90。Epub 2003年8月18日。
- PubMed ID
-
12925454 (在PubMed]
- 文摘
-
背景:补充,激活在心肌缺血和再灌注期间,通过多个进程导致心肌损伤。的补抑制心肌梗死治疗血管成形术(逗号)试验进行确定pexelizumab的影响,C5补体抑制剂,梗塞大小st段抬高心肌梗死(MI)患者主要接受经皮冠状动脉介入。方法和结果:在逗号,960 MI(20%孤立的劣质MI)患者随机安慰剂,pexelizumab 2.0毫克/公斤丸,或pexelizumab 2.0毫克/公斤丸和0.05毫克/公斤/ h注入20小时。梗塞大小肌酸kinase-MB曲线下面积,主要结果,组间没有显著差异(安慰剂中位数,4393;丸pexelizumab, 4526;丸+注入pexelizumab 4713 (ng / mL) x h;丸与安慰剂P = 0.89;P = 0.76丸+注入与安慰剂),综合90天死亡,也没有新的或恶化心脏衰竭、休克、或中风(安慰剂,11.1%;丸,10.7%;丸+注入,8.5%)。 The ninety-day mortality rate was significantly lower with pexelizumab bolus plus infusion (1.8% versus 5.9% with placebo; nominal P=0.014); the bolus-only group had an intermediate mortality rate (4.2%). CONCLUSIONS: In patients with ST-elevation MI undergoing percutaneous coronary intervention, pexelizumab had no measurable effect on infarct size. However, the significant reduction in mortality suggests that pexelizumab may benefit patients through alternative novel mechanisms and provides impetus for additional investigation.
DrugBank数据引用了这篇文章
- 药物